Monthly Prescribing Reference

Share this article:
Company Profile
MPR's mission is to develop integrated, multiplatform marketing communications programs for our pharmaceutical clients. To do so, we leverage the MPR brand's 23-year history of delivering concise, up-to-date drug information to over 500,000 clinicians. MPR delivers point-of-care messages to the healthcare professional's preferred media: mobile, desktop/laptop, online and print. Every digital program includes real-time, comprehensive metrics to measure ROI.

Products and Services
  • Key Words–ads targeted to brand name, generic name, or disease
  • Run-of-Site ads–includes impressions in therapeutic section
  • MPR Weekly News Brief–sponsorship of our opted-in Newsletter
  • MPR Prescribing Alerts–posted online or emailed eMPR Mobile and Desktop application
  • Digital Messages–targeted to Key Words, Section or Subsection
  • eMPR Sponsorships
  • Free download from sponsor's website
  • Sales force delivery on CD-ROM, USB Flash Drive or SD Card

Coming in 2008...
  • eMPR eDetail; eMPR Mobile Microsites and eMPR Monthly Sponsorship
  • Clinical Calculators and Clinical Chart Sponsorships
  • Mobile News and Alerts
Case Study
A major pharmaceutical brand was launching a comprehensive and informative web portal to support their target clinicians' information needs when sales reps were not present. Partners in this program needed to:
  • Supply valuable, independent content and tools
  • Provide sales force access tools to support reps
  • Build awareness of portal and drive repeat traffic
  • Generate leads and register/opt-in target clinicians
  • Deliver brand messages
  • Leverage alternative media channels

MPR developed a successful multi-platform, integrated year-long program that included digital and print single-sponsored editions, eMPR download and advertising/messaging opportunities. This program met all of the client's core objectives. An expanded program that builds on the successes of 2007 and incorporates new opportunities is expected to roll out in 2008.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...